Liver Fibrosis – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 87
Inquire Before Buying

Liver Fibrosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Liver Fibrosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Liver Fibrosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Liver Fibrosis.
- A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Liver Fibrosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Fibrosis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Liver Fibrosis 10
Liver Fibrosis Therapeutics under Development by Companies 12
Liver Fibrosis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Liver Fibrosis Therapeutics - Products under Development by Companies 19
Liver Fibrosis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Liver Fibrosis Therapeutics Development 21
Bristol-Myers Squibb Company 21
Gilead Sciences, Inc. 22
FibroGen, Inc. 23
Silence Therapeutics plc. 24
Genfit 25
La Jolla Pharmaceutical Company 26
LG Life Sciences, Ltd 27
Digna Biotech, S.L. 28
7TM Pharma A/S 29
GenKyoTex S.A. 30
Angion Biomedica Corp. 31
Virobay Inc. 32
Liver Fibrosis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
FG-3019 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TM-38837 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GFT-505 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
P-17 Systemic - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GM-CT-01 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VBY-376 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BB-3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GKT-137831 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
candesartan cilexetil - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
irbesartan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GS-6624 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CIGB-500 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AB-0023 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AM-095 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Raltegravir + Ritonavir-Boosted Protease Inhibitor - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cytopro - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GM-CT-02 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GR-MD-02 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GR-MD-01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ANG-4011 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-351 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug For Liver Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ANG-3298 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LC-280126 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79
Liver Fibrosis - Product Development Milestones 80
Featured News & Press Releases 80
Aug 07, 2012: New Drug Successfully Halts Fibrosis In Animal Model Of Liver Disease, Study Reports 80
Aug 07, 2012: Galectin Therapeutics Plans Clinical Trials For Early 2013 To Treat Fatty Liver Disease With Advanced Fibrosis After Recent FDA Meeting 80
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 81
May 10, 2012: Genfit Announces Preclinical Data Of GFT505 Promotes Liver Fibrosis Regression 82
Dec 16, 2011: Galectin Therapeutics Presents Preclinical Data On Treatment Of Fatty Liver Disease And Fibrosis At EASL 82
Nov 02, 2011: Promedior Announces Presentation Of Preclinical Data At AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis 83
Jul 12, 2011: GENFIT Announces First Results Of GFT505-210-5 Clinical Trial In Diabetic Patients 83
Apr 11, 2011: Fragment Of RegeneRx's Tß4 Inhibits Activation Of Liver Cells Responsible Fibrosis And Scar Formation 84
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 84
Oct 14, 2010: FibroGen Initiates Phase II Clinical Study To Evaluate Efficacy Of FG-3019 In Reversing Liver Fibrosis 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Bristol-Myers Squibb Company, H2 2012 21
Gilead Sciences, Inc., H2 2012 22
FibroGen, Inc., H2 2012 23
Silence Therapeutics plc., H2 2012 24
Genfit, H2 2012 25
La Jolla Pharmaceutical Company, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Digna Biotech, S.L., H2 2012 28
7TM Pharma A/S, H2 2012 29
GenKyoTex S.A., H2 2012 30
Angion Biomedica Corp., H2 2012 31
Virobay Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 38
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79

List of Figures
Number of Products under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

  • Anaesthesia Machine Industry is Flourishing due to an Extensive Customer Base with Therapeutic Needs
    The Anaesthesia Machine Industry comprises of the manufacturers and users of Anaesthesia Machines which are basically workstations or units that assist a person to administer Anaesthesia on the other. It includes plug & play Anaesthesia delivery units (ADUs). The industry also comprises of the various accessories like monitors and information systems and support services involved [...]
  • The Need for an Electric Cars Boosts The Lithium Sulfate Market
    Lithium is a highly demanded material. The popularity of this metal is primarily due to the characteristics of this metal and its compounds. Some of the characteristics of this material are that it has the highest electrochemical potential of all metals, a very high co-efficient of thermal expansion, acting as a viscosity modifier in melts, [...]
  • Tire Roller Industry
    Tire roller is one of the most popular equipment used in the construction industry. A tire roller offers multiple services from building highways, industrial sites, binder courses, wear courses and many more. Tire rollers come with different features like easy adjustment of tyres, flexible ballast, oscillating tires, etc. that facilitates in doing a particular work. [...]
  • The Adhesive Paper Industry Looking At a Long Term Bonding
    Adhesives are used extensively in the Paper Industry. They are primarily two kinds ie, the adhesive is either water based or hot melts. The kind of requirement determines the adhesive type in this industry. Adhesives have a wide arena of application. It is used as envelope gums, bookbinding adhesives, for lamination of paper, corrugated adhesives, [...]
  • The Rising Horizon of Maintenance Market of Wind Turbines
    Wind turbines have been one of the most economical means of means of electric production. There are a number of benefits for operating wind turbines. It negates the risk of price factor arising out of dwindling fuel prices and also is independent of pollution and fuel imports. This method of electric production is a capital [...]
  • The Oil Drilling Rig Industry
  • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and …

  • HER2-Negative Breast Cancer’s Therapeutic Market
  • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can cure …

  • The Market of Plate Heat Exchanger
  • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitations …

  • The Industry of Binding Machines
  • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the …

  • The Boom In Women Infertility Market
  • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Bioburden Testing Market by Product [Instrument (PCR, Microscopes), & Consumables (Kit, Reagent)], Test (Aerobic, Anaerobic, Fungi, Spore), Application (Raw Material, In-process) & End User (Pharmaceutical, Biotechnology, CMO) – Forecast to 2019
    Published: 14-May-2015        Price: US $4650 Onwards        Pages: 180
    The bioburden testing market is expected to reach $565.6 million by 2019 from $354.4 million in 2014, at a CAGR of 9.8% from 2014 to 2019. This market is segmented on the basis of products, test types, applications, end users, and regions. On the basis of end users, the market is segmented into pharmaceutical and biotechnology companies, medical device manufacturers, contract manufacturing organizations (CMOs), manufacturers of food & beverage and agricultural products, and microbial testing......
  • Japan Pharmaceuticals and Healthcare Report Q3 2015
    Published: 13-May-2015        Price: US $1295 Onwards        Pages: 153
    BMI View: The Japanese pharmaceutical market will become increasingly challenging for multinational drugmakers. This comes as the use of generic drugs has begun to gain momentum, creating a more competitive environment for innovative medicines. In addition, top line growth for foreign-based multinational drugmakers will be further challenged by the depreciation of the yen, which will remain weak under the country's 'Abenomics' economic initiative. Headline Expenditure Projections ? Pharmaceutica......
  • Global Medical Laser Systems Market 2015-2019
    Published: 13-May-2015        Price: US $2500 Onwards        Pages: 91
    Medical laser system consists of a wide variety of monochromatic light with a specific wavelength that has strong emission and is highly concentrated. The demand for lasers used in the field of medicine is increasing at a rapid rate due to the versatility of its light. The characteristics of laser light are defined by its power, wavelength, and pulsed or continuous wave operation. Laser light is best known for its laser tissue interaction: photothermal reactions, photochemical reactions, and pho......
  • Pakistan Pharmaceuticals and Healthcare Report Q3 2015
    Published: 13-May-2015        Price: US $1295 Onwards        Pages: 116
    BMI View: Medicine sales in Pakistan will continue to grow significantly from a low base. Underpinning this trajectory includes a reform in the country's pricing environment that will see scope for an increase in pharmaceutical prices. This will in turn encourage more investment from drugmakers to capture the commercial opportunities stemming from the country's epidemiological profile. Downside risks remain due to the lack of policy continuity and potential cost containment measures Headline Exp......
  • Global Peripheral Vascular Devices Market 2015-2019
    Published: 13-May-2015        Price: US $3000 Onwards        Pages: 101
    Peripheral vascular disease is a condition characterized by damage to or blockage in the peripheral blood vessels. This disease may result in the form of blood clots such as deep vein thrombosis, inflammation, or narrowing and blockage of the blood vessels. In case the peripheral vascular disease affects only the arteries, the condition is known as PAD. PAD is also considered one of the most serious complications in patients with diabetes. It is characterized by narrowed arteries due to the accu......
  • Poland Pharmaceuticals and Healthcare Report Q3 2015
    Published: 13-May-2015        Price: US $1295 Onwards        Pages: 113
    BMI View: The National Health Fund and the Agency for Health Technology Assessment will continue to impede the reimbursement of innovative drugs in Poland over the short term, given their current focus on budgetary restraint. Over the longer term, we expect these budgetary restrictions to ease and healthcare spending to accelerate, given our positive economic outlook for Poland. In light of our expectations, Poland will become a more attractive market to multinational drugmakers. Headline Expend......
  • Healthcare IT Market in Saudi Arabia 2015-2019
    Published: 13-May-2015        Price: US $2500 Onwards        Pages: 79
    Over the years, businesses in Saudi Arabia have been adopting advanced technologies and IT integration solutions to enhance their operations and revenue. With more and more operations being enabled and enriched by innovative IT applications and solutions, IT has become a key enabler of business functions. This trend is also being witnessed in the healthcare sector in Saudi Arabia. The need to maintain a standard record format has led to the transformation of traditional medical records to electr......
  • Tanzania Pharmaceuticals and Healthcare Report Q3 2015
    Published: 13-May-2015        Price: US $1295 Onwards        Pages: 84
    BMI View: The introduction of compulsory health insurance in Tanzania will increase uptake of the scheme among some sectors of the population. Despite the impressive employment rate, contributions from those employed in the informal and agriculture sectors will be less likely, limiting its uptake. Headline Expenditure Projections ? Pharmaceuticals: TZS797bn (USD479mn) in 2014 to an expected TZS909bn (USD496mn) in 2015; +14.0% growth in local currency terms and +3.5% in US dollar terms. Forecast ......
  • Austria Pharmaceuticals and Healthcare Report Q3 2015
    Published: 13-May-2015        Price: US $1295 Onwards        Pages: 74
    BMI View: The Austrian pharmaceutical and healthcare sectors are well developed and stable, offering some of the most attractive opportunities in the region. Nevertheless, our pharmaceutical and healthcare expenditure growth expectations remain resiliently subdued over the next few years, which prompted us to make downward revisions and caused a decline in Risk/Reward Index. Headline Expenditure Projections ? Pharmaceuticals: EUR4.45bn (USD5.96bn) in 2014 to EUR4.42bn (USD4.86bn) in 2015; -0.6% ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs